According to the report, the Global Acne Medication Market accounted for $8.07 billion in 2017 and is expected to reach $10.93 billion by 2025, registering a CAGR of 3.9% during the period from 2018 to 2025.
Increase in prevalence of acne diseases, unhealthy urban lifestyle, and surge in focus on skin care products are the major drivers of the global acne medication market. However, side effects associated with acne medications and presence of alternatives for acne treatment hamper the market growth. On the contrary, untapped potential in the emerging economies and rapid development of therapeutics with lesser side effects are expected to create lucrative opportunities in the near future.
Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4356
The global acne medication market is divided into therapeutic class, formulation, type, acne type, and distribution channel. On the basis of therapeutic class, the market is segmented into retinoids, antibiotics, salicylic acid, benzoyl peroxide, and others. The antibiotics segment held nearly one-fourth share of the total market in 2017.
Based on formulation, the market is segmented into topical medications and oral medications. The utilization rate of topical medications for acne treatment is the highest in the market, owing to high availability of such products with high success rate and lesser side effects. However, the oral medication segment is expected to manifest growth at a CAGR of 3.6% during the study period.
Based on type, the market is bifurcated into prescription medicines and over-the-counter medicines. The over-the-counter medicine segment is projected to grow at a CAGR of 2.9% through 2025. On the basis of acne type, the market is divided into non-inflammatory acne and inflammatory acne. The non-inflammatory acne segment held about two-fifths of the global market revenue in 2017. Based on distribution channel, the market is divided into grocery stores, pharmacies & drug stores, and e-commerce.
On the basis of geography, the market is divided into North America, Europe, Asia-Pacific, and LAMEA. Europe contributed about one-fourth of the total market in 2017. However, LAMEA is expected to offer profitable market growth opportunities, registering a CAGR of 4.5% during the forecast period. The North America region held the largest market share in 2017 and is expected to maintain its dominance throughout the study period, owing to early approval of acne medication products and high adoption of prescription medicines. However, Asia-Pacific region is projected to manifest the fastest CAGR of 5.6% during the study period, owing to increase in affordability, increase in healthcare expenditure, and surge in awareness toward safe acne medications products.
The report includes an analysis of the major market players including
- Allergan Plc.
- Johnson & Johnson
- Mylan N.V.
- GlaxoSmithKline Plc (Stiefel Laboratories Inc.)
- Teva Pharmaceutical Industries Ltd.
- Nestle S.A. (Galderma S.A.)
- Mayne Pharma Group Limited
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
- Valeant Pharmaceuticals International Inc.
Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/4356
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060